The Beauty Health Company (SKIN) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$0.93
Price Target
$1.30
Target Range
$1.00 — $1.60
Analyst Rating
Hold
Forward P/E—
Trailing P/E-5.8x
Forward PEG—
Implied Growth-132.0%
Median Target$1.30
Analyst Spread46.2%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$1
+7.2%
Consensus
$1
+39.4%
Bull Case
$2
+71.5%
SKIN Price Target Analysis
Updated May 7, 2026As of May 7, 2026, The Beauty Health Company (SKIN) has a Wall Street consensus price target of $1.30, based on estimates from 13 covering analysts. With the stock currently trading at $0.93, this represents a potential upside of +39.4%. The company has a market capitalization of $121M.
Analyst price targets range from a low of $1.00 to a high of $1.60, representing a 46% spread in expectations. The median target of $1.30 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 3 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 3 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, SKIN trades at a trailing P/E of -5.8x. Analysts expect EPS to grow -132.0% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Consumer Defensive stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+37.7%
Avg Forward P/E12.8x
Peers with Coverage9 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ELFe.l.f. Beauty, Inc. | $3.4B | $61.43 | $95.17 | +54.9% | Buy | 19.8x | 27 |
 IPARInter Parfums, Inc. | $3.0B | $94.81 | $107.50 | +13.4% | Hold | 19.6x | 19 |
 COTYCoty Inc. | $2.3B | $2.65 | $4.01 | +51.3% | Hold | 9.7x | 33 |
 NUSNu Skin Enterprises, Inc. | $354M | $7.34 | $11.00 | +49.9% | Hold | 7.3x | 11 |
 USNAUSANA Health Sciences, Inc. | $369M | $20.01 | $35.00 | +74.9% | Hold | 11.5x | 8 |
 ESTAEstablishment Labs Holdings Inc. | $2.2B | $74.68 | $85.00 | +13.8% | Buy | — | 14 |
 INMDInMode Ltd. | $861M | $13.59 | $16.00 | +17.7% | Buy | 9.4x | 11 |
 SSKNSTRATA Skin Sciences, Inc. | $5M | $0.14 | — | — | — | — | — |
 ULTAUlta Beauty, Inc. | $24.5B | $535.10 | $727.36 | +35.9% | Buy | 18.7x | 47 |
 SBHSally Beauty Holdings, Inc. | $1.4B | $13.98 | $17.75 | +27.0% | Hold | 6.8x | 30 |
Upside Potential Comparison
USNAELFCOTYNUSULTASBHINMDESTASee SKIN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SKIN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SKIN vs WMT
Side-by-side business, growth, and profitability comparison vs Walmart Inc..
Start ComparisonSKIN — Frequently Asked Questions
Quick answers to the most common questions about buying SKIN stock.
What is the SKIN stock price target for 2026?
The consensus Wall Street price target for SKIN is $1.3, representing 39.4% upside from the current price of $0.9327. With 13 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is SKIN a buy, sell, or hold?
SKIN has a consensus rating of "Hold" based on 13 Wall Street analysts. The rating breakdown is mixed, with 7 Hold ratings making up the largest segment. The consensus 12-month price target of $1.3 implies 39.4% upside from current levels.
Is SKIN stock overvalued or undervalued?
SKIN's current price is $0.9327 with a consensus target of $1.3 (39.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can SKIN stock go?
The most bullish Wall Street analyst has a price target of $1.6 for SKIN, while the most conservative target is $1. The consensus of $1.3 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover SKIN stock?
SKIN is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 7 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the SKIN stock forecast?
The 12-month SKIN stock forecast based on 13 Wall Street analysts shows a consensus price target of $1.3, with estimates ranging from $1 (bear case) to $1.6 (bull case). The median consensus rating is "Hold".
Should I buy SKIN stock?
Wall Street analysts are very optimistic on SKIN, with a "Hold" consensus rating and $1.3 price target (39.4% upside). 3 of 13 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do SKIN price targets vary so much?
SKIN analyst price targets range from $1 to $1.6, a 46% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $1.3 consensus represents the middle ground.